{"id":"NCT01876368","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan","officialTitle":"A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2014-08","completion":"2014-08","firstPosted":"2013-06-12","resultsPosted":"2015-12-07","lastUpdate":"2015-12-07"},"enrollment":376,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"LCZ696","otherNames":[]},{"type":"DRUG","name":"Olmesartan","otherNames":[]},{"type":"DRUG","name":"Placebo of LCZ696","otherNames":[]},{"type":"DRUG","name":"Placebo of Olmesartan","otherNames":[]}],"arms":[{"label":"LCZ696 200 mg","type":"EXPERIMENTAL"},{"label":"Olmesartan 20 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan","primaryOutcome":{"measure":"Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP)","timeFrame":"baseline, 8 weeks","effectByArm":[{"arm":"LCZ696 200 mg","deltaMin":-4.26,"sd":0.6},{"arm":"Olmesartan 20 mg","deltaMin":-1.04,"sd":0.61}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":51,"countries":["United States","Argentina","Guatemala","Philippines","Puerto Rico","Russia","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":188},"commonTop":["HEADACHE","DIZZINESS"]}}